ArticleTissue engineering and regenerative medicine2025
Synergistic Effect of Stromal Vascular Fraction and Lymph Node Transfer in a Rabbit Hindlimb Model.
Article in Tissue engineering and regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review.Frontiers in oncology · 2026Pooled it
- Cell-Free Adipose Liquid Extract Combined with Vascularized Lymph Node Transfer for Treating Lymphedema: Implications for Human Therapy.Tissue engineering and regenerative medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdipose-derived stem cells (ADSCs) promote lymphangiogenesis, though their integration with vascularized lymph node transfer (VLNT) is not well-explored. Unlike ADSCs, the stromal vascular fraction (SVF) can be obtained intraoperatively without the need for cell culture, making it ideal for incorporation into VLNT in a single-stage surgical procedure. This study evaluates the impacts of combined VLNT and SVF therapy using a rabbit hindlimb model.
methodNew Zealand white rabbits were divided into four groups: control, VLNT only, SVF only, and combined VLNT plus SVF. The VLNT procedure involved transferring a pedicled lymph node flap, while the SVF was harvested and injected into the perinodal tissue. Postoperative assessments included measuring edema volume, performing ICG lymphography, conducting histological analysis, and measuring VEGF-C and LYVE-1 expression.
resultsInitial increases in hindlimb edema volume were noted, but a significant decrease occurred by week 4, particularly in the VLNT group and VLNT plus SVF group compared to the control group. Histological evaluations indicated that the combined treatment group preserved superior structural integrity of the lymph nodes, with a decreased proportion of fibroadipose tissue compared to the VLNT-only group. Elevated VEGF-C expression was observed in the SVF-treated groups, as confirmed by both RT-PCR and ELISA analyses at week 4. Additionally, the combined VLNT plus SVF group showed increased LYVE-1 expression by week 8.
conclusionThe results suggest that SVF can be effectively integrated with VLNT in a single-stage procedure, enhancing the viability and structural integrity of vascularized lymph nodes. These results highlight the potential of this combined approach as a promising therapeutic strategy for advanced-stage lymphedema, meriting further exploration in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.